Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who receive...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Even, C., Lassen, U., Merchan, J., Le Tourneau, C., Soria, J-C, Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A., Massard, Christophe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2019
Konular:
Phase I Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066312/
https://ncbi.nlm.nih.gov/pubmed/30953269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00739-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller